Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
Tomoko Yamagishi-Dressler, the Chief Marketing Officer of Evolus, Inc. (NASDAQ:EOLS), a $840 million market cap company that has seen a robust 20% gain year-to-date, recently executed a sale of company stock, according to a regulatory filing. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 2.4. On March 18, Yamagishi-Dressler sold 4,536 shares of Evolus common stock, amounting to a total transaction value of $60,124. The shares were sold at an average price of $13.255 per share, with prices ranging from $13.1807 to $13.256. The company has demonstrated impressive revenue growth of 32% over the last twelve months.
The sale was conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks to avoid any potential insider trading violations. This particular sale was necessary to cover tax withholding obligations related to the vesting of certain Restricted Stock Units, as noted in the filing.
Following this transaction, Yamagishi-Dressler retains ownership of 95,671 shares of Evolus common stock.
In other recent news, Evolus announced its fourth-quarter 2024 financial results, reporting revenues of $79 million, which exceeded the expected $76.96 million and marked a 30% year-over-year increase. The company also achieved full-year revenues of $266.3 million, a 32% rise from the previous year, largely driven by strong U.S. product sales. Despite missing earnings per share (EPS) forecasts with a reported EPS of -$0.11 against an expected $0.02, Evolus achieved full-year profitability ahead of schedule. Looking forward, the company has provided optimistic guidance for 2025, projecting revenues between $345 million and $355 million, reflecting an anticipated growth of 30% to 33%.
The newly FDA-approved Evolysse products are expected to contribute significantly to this growth, accounting for 8% to 10% of the 2025 revenue. Analysts from Stifel and H.C. Wainwright have maintained their Buy ratings on Evolus, with price targets set at $25 and $27, respectively. They highlighted the company’s strong market penetration and the potential impact of new product launches. Evolus’s market share in the U.S. aesthetic toxin category continues to expand, supported by a significant increase in active accounts and record enrollment in its loyalty programs. The company is also focusing on expanding its international presence, with plans to achieve $700 million in revenue by 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.